Asean Poultry Vaccines Market Report: Market Size & Forecast 2026

ASEAN is one of the world's most significant poultry-producing regions, with Indonesia, Thailand, Vietnam, the Philippines, and Malaysia together accounting for a substantial share of Asia's chicken meat and egg output. The poultry vaccines market in the region is valued at roughly USD 480 million in 2025 and is projected to expand at around 9.1% annually through 2030. Commercial flock expansion, combined with heightened biosecurity requirements following repeated avian influenza outbreaks, underpins steady demand for both live attenuated and inactivated vaccines.

• •Estimated 2025 market value of approximately USD 0.48 billion, with a forecast CAGR near 9.1% through 2030.
• •Indonesia, Thailand, Vietnam, Malaysia, and the Philippines are the principal country-level markets within ASEAN.
• •Core disease targets include Newcastle disease, avian influenza, infectious bronchitis, Marek's disease, and infectious bursal disease.

Rising per-capita poultry consumption across Southeast Asia is pushing producers to scale up commercial operations, which in turn lifts vaccine volumes per flock cycle. Recurring outbreaks of highly pathogenic avian influenza (HPAI) and Newcastle disease have made prophylactic vaccination a standard practice rather than an option. Government interventions, including Indonesia's Ministry of Agriculture Decree No. 4026 on poultry vaccination and similar compulsory programs in Vietnam and Malaysia, are formalizing vaccine use across the value chain.

• •Growing regional demand for chicken meat and eggs is expanding the addressable commercial flock population.
• •Mandatory government vaccination programs are converting previously optional vaccination into a compliance requirement.
• •Increased biosecurity investment by integrators and contract growers is raising vaccine uptake per bird.

By vaccine type, the market is broadly split into live attenuated vaccines, inactivated (killed) vaccines, and recombinant or vector vaccines, with live attenuated products historically dominant due to cost and ease of mass administration via drinking water or spray. By disease indication, Newcastle disease and avian influenza account for the largest revenue shares, while Marek's and infectious bronchitis vaccines form important secondary segments. Geographically, Indonesia represents the single largest ASEAN market, followed by Vietnam and Thailand, with the Philippines and Malaysia growing rapidly from smaller bases.

• •Live attenuated vaccines lead in volume; recombinant and vector vaccines are the fastest-growing technology segment.
• •Newcastle disease and avian influenza vaccines together represent the majority of regional demand.
• •Indonesia is the largest country market, supported by scale and mandatory vaccination policy.

What are the recent trends and outlook?

The most visible structural trend is the gradual shift from conventional live and inactivated vaccines toward recombinant, vector, and combined (multivalent) vaccines that protect against several pathogens in a single dose. Vector-based HPAI and Newcastle disease vaccines are gaining traction as governments seek differentiated products compatible with DIVA (distinguishing infected from vaccinated animals) surveillance strategies. With a CAGR near 9.1%, the ASEAN market is on track to roughly double in value by 2030, and biologics manufacturers are expanding regional fill-finish capacity and distribution partnerships to capture that growth.

• •Recombinant and DIVA-compatible vaccines are the fastest-growing product category.
• •Producers are localizing manufacturing and distribution through joint ventures and contract manufacturing within ASEAN.
• •Long-term demand is reinforced by population growth, urbanization, and protein-diet diversification across Southeast Asia.